Sign Up Today and Learn More About Codagenix Stock
Invest in or calculate the value of your shares in Codagenix or other pre-IPO companies through EquityZen's platform.
Codagenix Stock (CODG)
Codagenix develops live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus.
About Codagenix Stock
Founded
2011
Headquarters
Farmingdale, NY, US
Industries
Software, Artificial Intelligence, Data and Analytics
Codagenix is a developer of live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus. Its vaccines utilize Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain.
Codagenix Press Mentions
Stay in the know about the latest news on Codagenix
Vaccine Developers Leverage mRNA and Other Powerful Technologies
genengnews • Aug 03, 2024
Respiratory Syncytial Virus Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Invest
openpr • Jan 19, 2024
First on CNN: HHS awards more than $500 million to study Covid-19 vaccine nasal sprays and more
cnn • Jan 19, 2024
Growing RSV Vaccine Market: Rapid Urbanization and ...
businesswire • Jan 19, 2024
JPM 2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development
biospace • Jan 12, 2024
Investors in Codagenix
Discover investors in Codagenix stock and explore their portfolio companies
Codagenix Management
Leadership team at Codagenix
Chief Medical Officer
Sybil Tasker
Chief Business Officer
Jeffrey Fu
Join now and verify your accreditation status to gain access to:
- Codagenix current valuation
- Codagenix stock price
- Available deals in Codagenix and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Codagenix Stock
How to invest in Codagenix stock?
Accredited investors can buy pre-IPO stock in companies like Codagenix through EquityZen funds. These investments are made available by existing Codagenix shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Codagenix stock?
Shareholders can sell their Codagenix stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
